[Metabolically designed treatments: from biochemistry to the vessel lining].
Moulin
P
P
Fédération d'endocrinologie diabétologie maladies métaboliques nutrition, hôpital cardiovasculaire Louis-Pradel, 69677 Bron, France. philippe.moulin@chu-lyon.fr
D001645:Biguanides / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002995:Clofibric Acid / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D001645:Biguanides; D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D045162:Thiazolidinediones; D002995:Clofibric Acid